Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab

被引:29
作者
Ellingson, Benjamin M. [1 ]
Cloughesy, Timothy F. [2 ]
Lai, Albert [2 ]
Nghiemphu, Phioanh L. [2 ]
Pope, Whitney B. [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA 90024 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA
关键词
functional diffusion map; fDM; glioblastoma; bevacizumab; diffusion MRI; HIGH-GRADE GLIOMA; BREAST MR-IMAGES; IMAGING BIOMARKER; NONRIGID REGISTRATION; MALIGNANT GLIOMAS; SURVIVAL; CELLULARITY; ECHO;
D O I
10.1002/mrm.23003
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Diffusion-weighted imaging estimates of apparent diffusion coefficient (ADC) have shown sensitivity to brain tumor cellularity as well as response to therapy. Functional diffusion maps (fDMs) exploit these principles by examining voxelwise changes in ADC within the same patient over time. Currently, the fDM technique involves linear image registration of ADC maps from subsequent follow-up times to pretreatment ADC maps; however, misregistration of ADC maps due to geometric distortions as well as mass effect from growing tumor can confound fDM measurements. In this study, we compare the use of a nonlinear registration scheme to the current linear fDM technique in 70 patients with recurrent glioblastoma multiforme treated with bevacizumab. Results suggest that nonlinear registration of pretreatment ADC maps to post-treatment ADC maps improves the clinical predictability, sensitivity, and specificity of fDMs for both progression-free and overall survival. Magn Reson Med, 2011. (C) 2011 Wiley-Liss, Inc.
引用
收藏
页码:237 / 245
页数:9
相关论文
共 31 条
[1]  
Andersson JL, 2008, ANN M ORG HUM BRAIN
[2]  
Andersson JLR., 2010, FMRIB Technical Report TR07JA2
[3]  
[Anonymous], 2007, TR07JA1 FMRIB
[4]  
CBTRUS, 2010, PRIM BRAIN TUM US 20
[5]   Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study [J].
Chen, Wei ;
Delaloye, Sibylle ;
Silverman, Daniel H. S. ;
Geist, Cheri ;
Czernin, Johannes ;
Sayre, James ;
Satyamurthy, Nagichettiar ;
Pope, Whitney ;
Lai, Albert ;
Phelps, Michael E. ;
Cloughesy, Timothy .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) :4714-4721
[6]   Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors [J].
Chenevert, TL ;
Stegman, LD ;
Taylor, JMG ;
Robertson, PL ;
Greenberg, HS ;
Rehemtulla, A ;
Ross, BD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (24) :2029-2036
[7]  
Cox RW, 1999, MAGNET RESON MED, V42, P1014, DOI 10.1002/(SICI)1522-2594(199912)42:6<1014::AID-MRM4>3.0.CO
[8]  
2-F
[9]   Comparison and evaluation of rigid, affine, and nonrigid registration of breast MR images [J].
Denton, ERE ;
Sonoda, LI ;
Rueckert, D ;
Rankin, SC ;
Hayes, C ;
Leach, MO ;
Hill, DLG ;
Hawkes, DJ .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1999, 23 (05) :800-805
[10]   Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas [J].
Ellingson, Benjamin M. ;
Malkin, Mark G. ;
Rand, Scott D. ;
LaViolette, Pete S. ;
Connelly, Jennifer M. ;
Mueller, Wade M. ;
Schmainda, Kathleen M. .
JOURNAL OF NEURO-ONCOLOGY, 2011, 102 (01) :95-103